BD's Latest Pen Needle Innovation Designed to Make Injections Easier for
People with Diabetes
Addition of EasyFlow™ Technology to BD Ultra-Fine™ Nano™ 4mm Pen Needles
Increases Confidence and Convenience of Injections
FRANKLIN LAKES, N.J., June 21, 2013
FRANKLIN LAKES, N.J., June 21, 2013 /PRNewswire/ -- BD Medical, a segment of
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical
technology company, announced today the U.S. launch of the BDUltra-Fine™
Nano™ 4mm Pen Needle with EasyFlow™ Technology. EasyFlow Technology makes it
easier and faster for people with diabetes to give themselves their daily
insulin injections. Product demonstrations will be taking place in the BD
booth at the American Diabetes Association 73rd Scientific Sessions on June 21
– 25, 2013 in Chicago.
(Photo: http://photos.prnewswire.com/prnh/20130621/NY36093-INFO )
Insulin is a life-saving drug for those unable to regulate their blood sugar
levels. For many people with diabetes, this means they will take the
medication for the rest of their lives, often with multiple injections per
day. People with diabetes recognize the impact of BD's latest innovation on
their daily injection experience, with a majority preferring BDUltra-Fine
Nano 4mm Pen Needles with EasyFlow Technology to their current pen needle on
all three of the leading insulin pen brands. In a clinical study published
in Clinical Therapeutics, 61% of patients reported they needed less thumb
force to inject, and 49% of patients reported less time to inject than with
their usual pen needle. BD is able to deliver this improved performance by
increasing the space inside the needle while maintaining industry leading
gauge size – increasing the flow rate in controlled laboratory testing by up
to 149% versus competitive pen needles.
The launch of EasyFlow Technology is the latest example of BD's commitment to
improving injections for people with diabetes. It follows BD's recent launch
of PentaPoint™ Comfort, a patented 5-bevel needle tip clinically proven to
enhance comfort. Both of these innovations are now included in BD's
shortest and thinnest pen needle, the BD Ultra-Fine Nano 4mm Pen Needle.
"Building on the introduction of BD's 4mm needle and 5-bevel PentaPoint
Comfort design, we are confident that our new EasyFlow Technology will provide
the most comfortable injection experience to help enable patients to adhere
more easily to their therapy regimens and ultimately improve their outcomes,"
said Linda Tharby, President, BD Medical – Diabetes Care.
BD's steady pace of patient friendly enhancements has caught the attention of
some important audiences. For example, BD Ultra-Fine Nano 4mm Pen Needles with
EasyFlow Technology have earned the Arthritis Foundation Ease-of-Use
Commendation, which recognizes products proven to make life easier for people
who have arthritis and other physical limitations. Independently tested by
experts and evaluated by people with arthritis, EasyFlow ^ Technology was
commended for ease of use when attaching, injecting, and dispensing medication
on select insulin pens for people with dexterity challenges.
EasyFlow Technology is currently available in the U.S. and Canada on all BD
Ultra-Fine Nano 4mm Pen Needles ^ with PentaPoint Comfort and will be
available in many European countries in the coming months. For more
information on how EasyFlow Technology and other BD innovations can help
improve outcomes for people with diabetes, visit www.bd.com/nano
Diabetes is a disease in which the body has a shortage of insulin or a
decreased ability to use insulin, a hormone that allows glucose (sugar) to
enter cells and be converted to energy. When diabetes is not controlled,
glucose and fats remain in the blood and, over time, damage vital organs.
Diabetes has become a national health concern in the United States, with an
estimated 26 million people - 8.3 percent of the population - living with the
disease. Of those people, an estimated 18.8 million have been diagnosed with
diabetes, and another 7 million are thought to be undiagnosed.If current
trends continue, as many as one in three U.S. adults will have diabetes by
2050. The total annual cost of diagnosed diabetes in the United States is
an estimated $245 billion.
For nearly 90 years, BD's culture of innovation and continuous improvement has
enhanced the patient experience to help improve therapy and outcomes for
people with diabetes worldwide. BD devices support earlier initiation and
better adherence to prescribed therapies to help all diabetes patients live
BD is a leading global medical technology company that develops, manufactures
and sells medical devices, instrument systems and reagents. The Company is
dedicated to improving people's health throughout the world. BD is focused on
improving drug delivery, enhancing the quality and speed of diagnosing
infectious diseases and cancers, and advancing research, discovery and
production of new drugs and vaccines. BD's capabilities are instrumental in
combating many of the world's most pressing diseases. Founded in 1897 and
headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000
associates in more than 50 countries throughout the world. The Company serves
healthcare institutions, life science researchers, clinical laboratories, the
pharmaceutical industry and the general public. For more information, please
 Aronson R., et al. (2013). Insulin pen needles: Effects of extra thin-wall
needle technology on preference, confidence, and other patient ratings.
Clinical Therapeutics, In Press, Corrected Proof, Available online 20 June
 Hirsch L.J., et al. (2012). Impact of a Modified Needle Tip Geometry on
Penetration Force as well as Acceptability, Preference, and Perceived Pain in
Subjects with Diabetes. Journal of Diabetes Science and Technology, 6(2),
 Boyle, J.P., Thompson, T.J., Gregg, E.W., et al. (2010). Projection of the
year 2050 burden of diabetes in the U.S. adult population: dynamic modeling of
incidence, mortality, and prediabetes prevalence. Population Health Metrics.
Retrieved from http://www.pophealthmetrics.com/content/8/1/29.
 American Diabetes Association. (2013). Economic Costs of Diabetes in the
U.S. in 2012. Diabetes Care. Retrieved from
BD Public Relations
SOURCE BD-Becton Dickinson
Press spacebar to pause and continue. Press esc to stop.